For effective pain relief

CORRECTIVE NOTICE

 

Published by order of the Federal Court of Australia

 

 

 

False and misleading conduct by AFT Pharmaceuticals (AU) Pty Ltd

 

The Federal Court has found that AFT Pharmaceuticals (AU) Pty Ltd

(AFT) engaged in false and misleading conduct through its Maxigesic

advertising campaign.

 

This follows legal action by

RECKITT BENCKISER (AUSTRALIA) PTY LIMITED.

 

From about March 2017 AFT published an advertising campaign

in pamphlets and later in magazines and cards for its Maxigesic

over-the-counter analgesic.

 

The Federal Court found that AFT engaged in misleading conduct

under the Australian Consumer Law when it represented that:

 

1. Maxigesic provides stronger and more effective relief from all pain than Nuromol when taken at their respective maximum recommended daily doses;
2. When taken at their respective maximum recommended daily doses, Maxigesic provides stronger and more effective relief from pain than any other paracetamol/ibuprofen combination
3. When taken at their respective maximum recommended daily doses, Maxigesic provides stronger and more effective relief from pain than OTC doses of either paracetamol or ibuprofen alone
4. Maxigesic reduces pain by at least 32% more than a full daily OTC dose of either paracetamol or ibuprofen alone throughout the period of administration of either drug;
5. there was a current adequate foundation in scientific knowledge for each of the representations set out in subparagraphs (i) to (iv) above

 

For further information contact AFT Pharmaceuticals Pty Ltd, Sydney

on 1800 2387 4276 or by email on receptionau@aftpharm.com